更正“异柠檬酸脱氢酶2突变通过Warburg效应促进急性髓系白血病阿糖胞苷耐药”

IF 3.9 4区医学 Q2 HEMATOLOGY

Hematological Oncology Pub Date : 2025-09-07 DOI:10.1002/hon.70133

{"title":"更正“异柠檬酸脱氢酶2突变通过Warburg效应促进急性髓系白血病阿糖胞苷耐药”","authors":"","doi":"10.1002/hon.70133","DOIUrl":null,"url":null,"abstract":"J. Yang, Z. Wang, K. Wu, et al. Isocitrate Dehydrogenase 2 Mutation Promotes Cytarabine Resistance in Acute Myeloid Leukemia by Warburg Effect. Hematological Oncology 42, no. 6 (2024): e3316. https://doi.org/10.1002/hon.3316.In the article, there were errors in Figures 1, 2 and 3. The representative flow cytometry results for HL-60 cell apoptosis, such as (KD-IHD2 group in Figure 1, WT + Enasidendb group in Figure 2, and IDH2 mutated group in Figure 3) were inadvertently used from different batches.The corrected figures are shown below. The authors confirmed that these corrections do not affect or alter the conclusion of the article.","PeriodicalId":12882,"journal":{"name":"Hematological Oncology","volume":"43 5","pages":""},"PeriodicalIF":3.9000,"publicationDate":"2025-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/hon.70133","citationCount":"0","resultStr":"{\"title\":\"Correction to “Isocitrate Dehydrogenase 2 Mutation Promotes Cytarabine Resistance in Acute Myeloid Leukemia by Warburg Effect”\",\"authors\":\"\",\"doi\":\"10.1002/hon.70133\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"J. Yang, Z. Wang, K. Wu, et al. Isocitrate Dehydrogenase 2 Mutation Promotes Cytarabine Resistance in Acute Myeloid Leukemia by Warburg Effect. Hematological Oncology 42, no. 6 (2024): e3316. https://doi.org/10.1002/hon.3316.In the article, there were errors in Figures 1, 2 and 3. The representative flow cytometry results for HL-60 cell apoptosis, such as (KD-IHD2 group in Figure 1, WT + Enasidendb group in Figure 2, and IDH2 mutated group in Figure 3) were inadvertently used from different batches.The corrected figures are shown below. The authors confirmed that these corrections do not affect or alter the conclusion of the article.\",\"PeriodicalId\":12882,\"journal\":{\"name\":\"Hematological Oncology\",\"volume\":\"43 5\",\"pages\":\"\"},\"PeriodicalIF\":3.9000,\"publicationDate\":\"2025-09-07\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1002/hon.70133\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Hematological Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/hon.70133\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hematological Oncology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/hon.70133","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

杨建军，王志强，吴克强，等。异柠檬酸脱氢酶2突变通过Warburg效应促进急性髓系白血病阿糖胞苷耐药。血液肿瘤学42号，no。6 (2024): e3316。https://doi.org/10.1002/hon.3316.In文章中，有错误在图1,2和3。HL-60细胞凋亡的代表性流式细胞术结果，如（图1中的KD-IHD2组，图2中的WT + Enasidendb组，图3中的IDH2突变组）无意中使用了不同批次的流式细胞术结果。更正后的数字如下所示。作者确认这些更正不会影响或改变文章的结论。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

Correction to “Isocitrate Dehydrogenase 2 Mutation Promotes Cytarabine Resistance in Acute Myeloid Leukemia by Warburg Effect”

查看原文本刊更多论文

Correction to “Isocitrate Dehydrogenase 2 Mutation Promotes Cytarabine Resistance in Acute Myeloid Leukemia by Warburg Effect”

J. Yang, Z. Wang, K. Wu, et al. Isocitrate Dehydrogenase 2 Mutation Promotes Cytarabine Resistance in Acute Myeloid Leukemia by Warburg Effect. Hematological Oncology 42, no. 6 (2024): e3316. https://doi.org/10.1002/hon.3316.

In the article, there were errors in Figures 1, 2 and 3. The representative flow cytometry results for HL-60 cell apoptosis, such as (KD-IHD2 group in Figure 1, WT + Enasidendb group in Figure 2, and IDH2 mutated group in Figure 3) were inadvertently used from different batches.

The corrected figures are shown below. The authors confirmed that these corrections do not affect or alter the conclusion of the article.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Hematological Oncology 医学-血液学

CiteScore

4.20

自引率

6.10%

发文量

147

审稿时长

>12 weeks

期刊介绍： Hematological Oncology considers for publication articles dealing with experimental and clinical aspects of neoplastic diseases of the hemopoietic and lymphoid systems and relevant related matters. Translational studies applying basic science to clinical issues are particularly welcomed. Manuscripts dealing with the following areas are encouraged: -Clinical practice and management of hematological neoplasia, including: acute and chronic leukemias, malignant lymphomas, myeloproliferative disorders -Diagnostic investigations, including imaging and laboratory assays -Epidemiology, pathology and pathobiology of hematological neoplasia of hematological diseases -Therapeutic issues including Phase 1, 2 or 3 trials as well as allogeneic and autologous stem cell transplantation studies -Aspects of the cell biology, molecular biology, molecular genetics and cytogenetics of normal or diseased hematopoeisis and lymphopoiesis, including stem cells and cytokines and other regulatory systems. Concise, topical review material is welcomed, especially if it makes new concepts and ideas accessible to a wider community. Proposals for review material may be discussed with the Editor-in-Chief. Collections of case material and case reports will be considered only if they have broader scientific or clinical relevance.